A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer

This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[68Ga\]/ \[131I\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.

Trial Details

NCT ID
NCT07707531
Phase
EARLY_PHASE1
Sponsor
Huashan Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • [68Ga]/ [131I]-IR199
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Informed consent must be obtained in writing from the subject, their legally authorized representative, or caregiver.
  • Age equal to or above 18 years old.
  • Histologically or cytologically confirmed gastric cancer or pancreatic cancer with Claudin 18.2 expression.
  • Must have ≥1 Claudin 18.2 positive lesions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →